- Home
- SGLY vs CHEK Comparison
SGLY vs CHEK Comparison
Compare SGLY & CHEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGLY
- CHEK
- Stock Information
- Founded
- SGLY 2001
- CHEK 2004
- Country
- SGLY United States
- CHEK Israel
- Employees
- SGLY N/A
- CHEK N/A
- Industry
- SGLY
- CHEK Medical Electronics
- Sector
- SGLY
- CHEK Health Care
- Exchange
- SGLY Nasdaq
- CHEK Nasdaq
- Market Cap
- SGLY 4.5M
- CHEK 3.9M
- IPO Year
- SGLY 2008
- CHEK 2015
- Fundamental
- Price
- SGLY $1.26
- CHEK $2.60
- Analyst Decision
- SGLY
- CHEK
- Analyst Count
- SGLY 0
- CHEK 0
- Target Price
- SGLY N/A
- CHEK N/A
- AVG Volume (30 Days)
- SGLY 61.9K
- CHEK 8.7M
- Earning Date
- SGLY 11-13-2025
- CHEK 11-14-2025
- Dividend Yield
- SGLY N/A
- CHEK N/A
- EPS Growth
- SGLY N/A
- CHEK N/A
- EPS
- SGLY N/A
- CHEK N/A
- Revenue
- SGLY $2,172,036.00
- CHEK N/A
- Revenue This Year
- SGLY N/A
- CHEK N/A
- Revenue Next Year
- SGLY N/A
- CHEK N/A
- P/E Ratio
- SGLY N/A
- CHEK N/A
- Revenue Growth
- SGLY N/A
- CHEK N/A
- 52 Week Low
- SGLY $0.54
- CHEK $0.56
- 52 Week High
- SGLY $5.49
- CHEK $3.13
- Technical
- Relative Strength Index (RSI)
- SGLY 65.52
- CHEK 85.94
- Support Level
- SGLY $1.11
- CHEK $0.65
- Resistance Level
- SGLY $1.45
- CHEK $3.13
- Average True Range (ATR)
- SGLY 0.10
- CHEK 0.27
- MACD
- SGLY 0.02
- CHEK 0.22
- Stochastic Oscillator
- SGLY 62.75
- CHEK 76.60
About SGLY Singularity Future Technology Ltd.
Singularity Future Technology Ltd is an investment holding company. The company's operating segment includes Freight Logistics Services and Sale of Crypto-mining Machines. It generates maximum revenue from the Freight Logistics Services segment. Geographically, it derives a majority of its revenue from China.
About CHEK Check-Cap Ltd.
Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.